News | May 19, 2023
Gland Pharma posts Q4 FY23 consolidated PAT at Rs. 78.68 Cr
Gland Pharma has reported total income of Rs. 823.95 crores during the period ended March 31, 2023
Gland Pharma has reported total income of Rs. 823.95 crores during the period ended March 31, 2023
The United States Food and Drug Administration (USFDA) conducted an inspection at Gland Pharma Limited API Facility at JNPC, Visakhapatnam
The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility
Supriya Lifescience Limited has informed that the European Directorate for the Quality of Medicines (EDQM) has granted Attestation of Inspection (EU-GMP) for Lote API Facility, Ratnagiri, Maharashtra.
Gland Pharma enters into a Put Option Agreement to acquire 100% of Cenexi Group
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Subscribe To Our Newsletter & Stay Updated
